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Abstract
The complete pathological response after primary chemotherapy could represent an important
prognostic factor in patients affected by colorectal liver metastases.
In recent studies, increasing complete pathological response seems to be correlated with longer
overall survival periods and it is recognized as an important prognostic factor in patients treated
with pre-operative chemotherapy.
The correlation of radiological information on residual neoplastic disease after neoadjuvant
treatment, obtained with CT and PET, has to be evaluated; in fact the complete disappearance of
liver metastasis on radiological imaging does not always mean a complete disappearance of tumor
tissue on histological examination; when it is documented with surgical procedures and confirmed
by pathologist's examination, we can consider the complete pathological response.
In recent years the addition of monoclonal antibodies to conventional chemotherapy may further
increase the proportion of patients referred for surgery; bevacizumab before surgery has been
shown to be feasible and safe, although concerns still exist regarding possible post-surgical and
wound healing complications or bleeding. The limitation of the radiologic assessment of response
as a surrogate for pathological response is even more relevant when antiangiogenic treatments are
used. Excellent responses to bevacizumab-containing regimens do occur and referral to surgical
oncology is a crucial step for documentation of complete pathological response.
Background
At present, the only available treatment associated with
long-term survival in patients with colorectal cancer
metastases is liver resection with 5-year survival rates rang-
ing from 21% to 58%[1]. Unfortunately, only 10% to
25% of patients with colorectal liver metastases are eligi-
ble for surgical resection. The standard of care in unresect-
able patients is palliative chemotherapy in order to
improve overall survival; however, chemotherapy may
also be used in an attempt to render liver metastases ame-
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apy, resections of initially unresectable liver metastases
have been reported in about 13% of patients [2] with suc-
cessful 5-year overall survival comparable to patients pri-
marily respectable[3].
In resectable patients, pre-operative chemotherapy may
increase the R0 resection rate and facilitate limited hepa-
tectomies, hence sparing normal liver parenchyma and
improving post-operative recovery[4]. The objective of
this approach is also to control the metastatic disease in
order to avoid surgery in patients with rapidly progressive
disease associated with a poor outcome after hepatic
resection[5]. Progressively, pCR seems to be correlated
with longer overall survival periods and is recognized as
an important prognostic factor in patients treated with
pre-operative chemotherapy for breast, esophageal, gastric
and rectal cancer primitive tumors [6,7].
Interestingly, the pCR, still reported as a rare situation
with an overall incidence of 4% of all resected patients, is
going to achieve clinical significance implying the com-
plete absence of residual neoplastic tissue on examination
by a pathologist [8]. In a recent study by Adam et al., the
pCR of liver metastases was associated with a 5-year over-
all survival of 76%[9].
Complete metabolic response on PET scan after neoadju-
vant chemotherapy is not always a reliable indicator of
pCR. Even though the PET scan has the advantage of com-
bining functional and anatomic imaging in an integrated
scanner, discordant data from the literature indicate the
limitations of the PET scan in restaging patients with
hepatic colorectal metastases following neoadjuvant
chemotherapy; surgical decision-making often requires
information from multiple modalities. Lesions not seen
on imaging are still found to have viable tumors when
resected or to lead to recurrence without resection[10].
pCR is described as being more frequent than CR, indicat-
ing that total necrosis of tumor cells does not imply disap-
pearance of metastasis in pre-operative imaging and does
not necessarily correspond to CR[9].
In recent years, novel biological agents have also changed
the standard of care for metastatic colorectal cancer and
may have implications for neoadjuvant treatment The
limitation of the radiologic assessment of response as a
surrogate for pathological response is even more relevant
when antiangiogenic treatments are used.
We report a case of pCR after primary chemotherapy of
four courses of FOLFOX-6 plus bevacizumab (much
shorter than expected because of poor tolerability) of
colorectal liver metastases confirmed by laparoscopic liver
biopsies; CT and PET scans showed good correspondence
between the two imaging techniques and between clinical
and pathological response. After 36 months, the patient is
alive and disease free.
Case presentation
In June 2006, a healthy 72-year-old woman presented
with rectal bleeding, which had started a few weeks
before, and without significant anemia or clinical symp-
toms. In her medical history, no prior pathological condi-
tions, no familial cancer or concomitant medications
were reported. Endoscopic examination revealed a volu-
minous neoplastic mass in the cecal tract of the colon
without obstruction; a biopsy of the lesion established the
diagnosis of adenocarcinoma. At computed tomography
(CT) scan, multiple liver metastases (16 lesions with 1.5
cm as the largest diameter) were detected. The patient
underwent a right hemicolectomy and the pathology
report showed a moderately differentiated adenocarci-
noma of the cecal tract invading the adipose perivisceral
tissue with metastatic involvement in one of the 23 nodes
removed (pT3N1). Surgical biopsy of a liver lesion con-
firmed the presence of metastatic disease. A positron
emission tomography (PET) scan showed a standardized
uptake value (SUV) of ≥8 of liver lesions and the absence
of extra-hepatic uptake (Fig. 1). The patient was entered
into a phase II clinical trial of FOLFOX-6 plus bevacizu-
mab 5 mg/kg, every 2 weeks. After the first course of ther-
apy, the patient experienced a G3 neutropenia and
subsequent chemotherapy doses were reduced to 75%
while maintaining the initially planned dose of bevacizu-
mab. In spite of dose reduction, the patient again experi-
a, b, c – Imaging before primary treatment: multiple liver metastases and no extra hep tic disease described by CT and PETFigure 1
a, b, c – Imaging before primary treatment: multiple 
liver metastases and no extra hepatic disease 
described by CT and PET.
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requiring hospitalization.
Because of poor tolerability, a CT scan and a PET scan
were performed after four courses of treatment (instead of
the initially planned six courses) and did not reveal any
liver metastases (Fig 2). The patient was referred to a sur-
geon: a laparoscopy was performed with ultrasound-
guided multiple liver biopsies. At pathology, no tumor
cells were detected. Because of the documented patholog-
ical CR and prior toxicities, no further therapy was given.
After 36 months, the patient is alive and disease free.
Discussion
This case report underlines the atypical clinical experience
of a good outcome in advanced malignant disease. Wide-
spread liver involvement is a major source of morbidity
and eventually leads to death in the vast majority of such
individuals with poor chances of a radical surgical man-
agement, the only available treatment associated with
long-term survival. The standard of care for metastatic
unresectable colorectal cancer is represented by systemic
chemotherapy that can be administered to prolong sur-
vival and is considered palliative. Nevertheless, reports of
successful resections in these patients following systemic
chemotherapy could shift it from being a palliative to a
curative treatment. The introduction of monoclonal anti-
body in a clinical phase II study setting could encourage
this intention.
In our patient, the primary treatment was administered
for only a short period, much shorter than anticipated and
the drug dosages were also decreased in order to reduce
the possibility of toxicity events; consequently, discontin-
uation of therapy was anticipated. Nevertheless, the
patient achieved a CR that was later documented to be a
pCR with a disease-free survival longer than 36 months
and which is still persistent.
A recent study showed that the rates of radical surgery are
better in the group of patients receiving bevacizumab
together with oxaliplatin-based regimen chemotherapy
versus oxaliplatin-chemotherapy alone administered with
neoadjuvant purpose [11]. It is notable that this result,
achieved despite the short duration of primary treatment,
confirms other similar experiences indicating that two to
four cycles of the combination of fluoropyrimidine plus
oxaliplatin and bevacizumab are not less effective than
longer treatment based on cytotoxic therapy without bev-
acizumab, with regard to pathologic response [12].
It should be noted that primary metastatic cancer patients
usually have unfavorable prognosis and palliative chemo-
therapy has the objective to prolong overall survival.
However, pCR was achieved with crucial improvement in
the prognosis for the patient.
In clinical practice, an important open debate is the histo-
logical confirmation of complete CR. A complete disap-
pearance of metastases on radiological imaging does not
always mean a complete disappearance of tumor tissue on
pathological examination. The eventuality of pCR should
be taken into consideration in all patients with complete
CR in order to avoid additional chemotherapy; on the
other side, still persistent tumour can undergo to radical
surgery in resectable patients. In addition to this, patho-
logic analysis can represent a possible evaluation of
tumour response after prior treatments or hepatic injury
of the nontumours liver to cytotoxic therapy.
In our patient, a complete correspondence of radiological
imaging was observed. Contrast enhanced CT scan and
PET scan did not reveal any liver lesions establishing the
reliable sensitivity of different modalities in the evalua-
tion of colon liver lesions after chemotherapy. In our
patient, both CT and PET imaging have demonstrated
adequate sensitivity to predict pathological response.
These congruences, described first between different imag-
ing techniques and secondarily between radiological
assessments and the pathologist's report, are not always
present and more accurate imaging reflecting the meta-
bolic activity of tumor cells can become necessary.
Conclusion
The addition of bevacizumab to primary chemotherapy
could increase the rate of pCR in liver metastatic CRC
patients and may help to improve survival rates in
patients with initially unresectable liver disease. Excellent
a, b, c – Imaging after 4 courses of primary treatment, cCR described by CT, PET and liver ultrasound with contrastFigure 2
a, b, c – Imaging after 4 courses of primary treat-
ment, cCR described by CT, PET and liver ultra-
sound with contrast.Page 3 of 4
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responses to bevacizumab-containing regimes do occur
and the referral to surgical oncology is a crucial step for
documentation of pCR.
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